{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:40:30Z","timestamp":1771706430857,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T00:00:00Z","timestamp":1334880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Hypertension is the most prevalent and potentially modifiable risk factor for atrial fibrillation (AF). In a previous secondary prevention study, the authors observed that the angiotensin II receptor blocker telmisartan was more effective than the calcium channel blocker amlodipine in preventing AF relapse in hypertensive patients with normal atrial size.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis:<\/jats:title><jats:p>Telmisartan may be more effective than amlodipine in preventing AF recurrence in hypertensive patients with paroxysmal AF and normal or increased left atrial dimension (LAD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>The authors assigned 378 mild hypertensive outpatients in sinus rhythm, but with \u22652 episodes of AF in the previous 6 months, to 1 of 2 groups. Group 1 comprised patients with LAD &lt;40 mm in females and &lt;45 mm in males. Group 2 comprised patients with LAD &gt;40 mm and &lt;45 mm in females and &gt;45 mm and &lt;50 mm in males. In both groups, patients were randomly treated with telmisartan or amlodipine for 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Systolic and diastolic blood pressure were similarly reduced by telmisartan and amlodipine in both groups. The AF recurrence rate was significantly lower in the telmisartan\u2010treated patients than in the amlodipine\u2010treated patients in both group 1 (12 vs 39, <jats:italic>P &lt;<\/jats:italic> 0.01) and group 2 (40 vs 59, <jats:italic>P &lt;<\/jats:italic> 0.05). Under telmisartan, the AF recurrence rate was significantly lower in group 1 than in group 2 (12.9% vs 42.1%, <jats:italic>P &lt;<\/jats:italic> 0.05). Time to a first AF relapse was significantly longer with telmisartan than with amlodipine in both group 1 (176 \u00b1 94 days vs 74 \u00b1 61 days, <jats:italic>P &lt;<\/jats:italic> 0.05) and group 2 (119 \u00b1 65 days vs 38 \u00b1 35 days, <jats:italic>P &lt;<\/jats:italic> 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Telmisartan was more effective than amlodipine in preventing AF recurrences in hypertensive patients with paroxysmal AF. <jats:italic>Clin. Cardiol.<\/jats:italic> 2012 DOI: 10.1002\/clc.21994<\/jats:p><jats:p>The authors have no funding, financial relationships, or conflicts of interest to disclose.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.21994","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T17:52:26Z","timestamp":1334944346000},"page":"359-364","source":"Crossref","is-referenced-by-count":26,"title":["Effect of Telmisartan on Paroxysmal Atrial Fibrillation Recurrence in Hypertensive Patients With Normal or Increased Left Atrial Size"],"prefix":"10.1002","volume":"35","author":[{"given":"Roberto","family":"Fogari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Zoppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"Mugellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Preti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00583-9"},{"key":"e_1_2_6_3_2","unstructured":"European Heart Rhythm Association European Association for Cardio\u2010Thoracic Surgery Camm AJ Kirchhof P Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369\u20132429."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.065"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000052830.02773.E4"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328338c20e"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.1998.tb00114.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.026"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.03.019"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2007.10.022"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.137760"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ejechocard\/jeq176"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.24.2765"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753944708092111"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.09.014"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi350"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.043"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e32833cdd6f"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000022665.18619.83"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","article-title":"Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long\u2010standing persistent atrial fibrillation: results of a prospective and controlled study.","volume":"24","author":"Ueng KC","year":"2003","journal-title":"Eur Heart J."},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/eurheartj\/ehl135","article-title":"Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.","volume":"27","author":"Yin Y","year":"2006","journal-title":"Eur Heart J."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000193808.99773.28"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2008.217"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1074248410395018"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2006.08.086","article-title":"Candesartan in the prevention of relapsing atrial fibrillation.","volume":"120","author":"Tveit A","year":"2007","journal-title":"Int J Cardiol."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805710"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.965178"},{"key":"e_1_2_6_28_2","first-page":"41","article-title":"Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.","volume":"25","author":"Kakuta H","year":"2005","journal-title":"Int J Clin Pharmacol Res."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1237359"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.29.849"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.457"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000123072.34629.57"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1083811"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1686"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000086979.39843.7B"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.02.048"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.21994","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.21994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:41:23Z","timestamp":1700563283000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.21994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,20]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/clc.21994"],"URL":"https:\/\/doi.org\/10.1002\/clc.21994","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,20]]}}}